KRAS^G12C Inhibitors in Non-Small Cell Lung Cancer: A Review.

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-08-24 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S473368

Min Tang, Yijun Wu, Xiufeng Bai, You Lu

引用次数: 0

Abstract

Rat sarcoma virus (RAS) GTPase is one of the most important drivers of non-small cell lung cancer (NSCLC). RAS has three different isoforms (Harvey rat sarcoma viral oncogene homolog [HRAS], Kirsten rat sarcoma viral oncogene homolog [KRAS] and Neuroblastoma ras viral oncogene homolog [NRAS]), of which KRAS is most commonly mutated in NSCLC. The mutated KRAS protein was historically thought to be "undruggable" until the development of KRAS^G12C inhibitors. In this review, from the aspect of brain metastasis, we aim to provide an overview of the advances in therapies that target KRAS^G12C, the limitations of the current treatments, and future prospects in patients with KRAS p.G12C mutant NSCLC.

查看原文本刊更多论文

非小细胞肺癌中的 KRASG12C 抑制剂：综述。

大鼠肉瘤病毒（RAS）GTPase 是导致非小细胞肺癌（NSCLC）的最重要因素之一。RAS 有三种不同的异构体（哈维大鼠肉瘤病毒癌基因同源物 [HRAS]、克尔斯滕大鼠肉瘤病毒癌基因同源物 [KRAS] 和神经母细胞瘤 ras 病毒癌基因同源物 [NRAS]），其中 KRAS 在 NSCLC 中最常发生突变。在开发出 KRASG12C 抑制剂之前，突变的 KRAS 蛋白一直被认为是 "不可救药 "的。在这篇综述中，我们将从脑转移的角度概述针对 KRASG12C 的疗法的进展、当前疗法的局限性以及 KRAS p.G12C 突变 NSCLC 患者的未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.

KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review.

Abstract

KRAS^G12C Inhibitors in Non-Small Cell Lung Cancer: A Review.